

Resource Summary Report

Generated by [RRID](#) on Aug 19, 2026

pBABEpuro-ERBB2 A775_G776insYVMA

RRID:Addgene_40982

Type: Plasmid

Proper Citation

RRID:Addgene_40982

Plasmid Information

URL: <http://www.addgene.org/40982>

Proper Citation: RRID:Addgene_40982

Insert Name: ERBB2

Organism: Homo sapiens

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:22908275](#)

Vector Backbone Description: Backbone Size:5200; Vector Backbone:pBABE-puro; Vector Types:Mammalian Expression, Retroviral; Bacterial Resistance:Ampicillin

Plasmid Name: pBABEpuro-ERBB2 A775_G776insYVMA

Relevant Mutation: A775_G776insYVMA

Record Creation Time: 20220422T222212+0000

Record Last Update: 20260815T081440+0000

Ratings and Alerts

No rating or validation information has been found for pBABEpuro-ERBB2 A775_G776insYVMA.

No alerts have been found for pBABEpuro-ERBB2 A775_G776insYVMA.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Lu Y, et al. (2026) Characterization of HER2-Positive Murine Breast Cancer Models for Investigating HER2-Targeted Therapy and Immunotherapy. *Cancers*, 18(6).

Werner RL, et al. (2022) Single-cell analysis reveals the Comma-1D cell line as a unique model for mammary gland development and breast cancer. *Journal of cell science*, 135(10).

Bi Y, et al. (2021) DEPTOR stabilizes ErbB2 to promote the proliferation and survival of ErbB2-positive breast cancer cells. *Theranostics*, 11(13), 6355.

Robichaux JP, et al. (2019) Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Pozotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. *Cancer cell*, 36(4), 444.

Thaler S, et al. (2017) Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. *Oncotarget*, 8(42), 72281.